|
|
 |
|
| Drug |
Lead
Company |
Target (sort) |
Phase (sort) |
Est. Approval
Date |
Likelihood of
Approval |
Peak U.S. Revenue
(M) |
| Proleukin |
Chiron
Corporation (CHIR) |
IL-2
receptor |
Approved (Clinical
Detail) |
05/92 |
100% (Same As
Avg.) |
$
42.9 |
| Sorafenib
|
Onyx
Pharmaceuticals, Inc. (ONXX) |
Tyrosine
Kinases |
NDA (Clinical
Detail) |
01/06 |
91% ( 10% Above Avg.)
|
$
52.4 |
| Sutent |
Pfizer,
Inc. (PFE) |
Tyrosine
Kinases |
NDA (Clinical
Detail) |
02/06 |
89% ( 8% Above Avg.)
|
$
170.9 |
| Avastin |
Genentech,
Inc. (DNA) |
VEGF |
III (Clinical
Detail) |
07/07 |
77% ( 10% Above Avg.)
|
$
288.8 |
| Oncophage |
Antigenics,
Inc. (AGEN) |
Immune
system |
III (Clinical
Detail) |
01/07 |
62% ( 5% Below Avg.)
|
N/A |
| Temsirolimus |
Wyeth
(WYE) |
mTOR |
III (Clinical
Detail) |
01/07 |
72% ( 5% Above Avg.)
|
$
47.4 |
| Thalomid |
Celgene
Corporation (CELG) |
Angiogenesis |
II/III (Clinical
Detail) |
01/09 |
37% ( 30% Below Avg.)
|
$
5.0 |
| AG-013736 |
Pfizer,
Inc. (PFE) |
Tyrosine
Kinases |
II (Clinical
Detail) |
01/09 |
30% (Same As
Avg.) |
N/A |
| Ceplene |
Maxim
Pharmaceuticals, Inc. (MAXM) |
Histamine 2
Receptor (H2R) |
II (Clinical
Detail) |
01/11 |
10% ( 20% Below Avg.)
|
N/A |
| Genasense
|
Genta,
Inc. (GNTA) |
Bcl-2 |
II (Clinical
Detail) |
01/11 |
25% ( 5% Below Avg.)
|
$
1.5 |
| Gleevec |
Novartis
AG (NVS) |
Tyrosine
Kinases |
II (Clinical
Detail) |
01/11 |
15% ( 15% Below Avg.)
|
N/A |
| GTI-2040 |
Lorus
Therapeutics Inc. (LRP) |
ribonucleotide
reductase (RNR) |
II (Clinical
Detail) |
01/09 |
33% ( 3% Above Avg.)
|
N/A |
| IMOxine |
Hybridon,
Inc. (HYBN) |
Toll-like
receptor 9 (TLR9) |
II (Clinical
Detail) |
01/11 |
30% (Same As
Avg.) |
N/A |
| Iressa
|
AstraZeneca
PLC (AZN) |
Epidermal
Growth Factor Receptor (EGFR) |
II (Clinical
Detail) |
01/11 |
20% ( 10% Below Avg.)
|
$
0.9 |
| Ispinesib |
Cytokinetics,
Inc (CYTK) |
Kallikrein |
II (Clinical
Detail) |
01/12 |
30% (Same As
Avg.) |
N/A |
| M200 |
Protein
Design Labs, Inc. (PDLI) |
Integrin |
II (Clinical
Detail) |
01/12 |
30% (Same As
Avg.) |
N/A |
| MDX-010 |
Medarex,
Inc. (MEDX) |
CTLA-4 |
II (Clinical
Detail) |
01/11 |
30% (Same As
Avg.) |
N/A |
| MG98 |
MethylGene
Inc. |
DNA
Methyltransferase |
II (Clinical
Detail) |
01/11 |
30% (Same As
Avg.) |
N/A |
| Panitumumab |
Abgenix,
Inc. (ABGX) |
Epidermal
Growth Factor Receptor (EGFR) |
II (Clinical
Detail) |
01/11 |
31% ( 1% Above Avg.)
|
$
1.1 |
| Revlimid |
Celgene
Corporation (CELG) |
Angiogenesis |
II (Clinical
Detail) |
01/10 |
20% ( 10% Below Avg.)
|
$
6.0 |
| Tarceva |
OSI
Pharmaceuticals, Inc. (OSIP) |
Epidermal
Growth Factor Receptor (EGFR) |
II (Clinical
Detail) |
01/11 |
35% ( 5% Above Avg.)
|
$
47.3 |
| Targretin
capsules |
Ligand
Pharmaceuticals, Inc. (LGND) |
Retinoid X
receptors (RXRs) |
II (Clinical
Detail) |
01/11 |
30% (Same As
Avg.) |
$
2.2 |
| Velcade |
Millennium
Pharmaceuticals Inc. (MLNM) |
Proteasome |
II (Clinical
Detail) |
01/12 |
22% ( 8% Below Avg.)
|
$
4.8 |
| Xcytrin |
Pharmacyclics,
Inc. (PCYC) |
growth
factors |
II (Clinical
Detail) |
01/10 |
30% (Same As
Avg.) |
N/A |
| AS1411 |
Antisoma
plc. (ASM) |
Nucleolin |
I (Clinical
Detail) |
N/A |
20% (Same As
Avg.) |
N/A |
| Dacogen |
SuperGen,
Inc. (SUPG) |
DNA
Methyltransferase |
I (Clinical
Detail) |
N/A |
20% (Same As
Avg.) |
N/A |
| IL-21 |
ZymoGenetics,
Inc. (ZGEN) |
IL-21 |
I (Clinical
Detail) |
N/A |
20% (Same As
Avg.) |
N/A |
| Neovastat |
AEterna
Zentaris (AEZS) |
Matrix
Metalloproteinase |
Suspended (Clinical
Detail) |
N/A |
1%
( 1% Above
Avg.) |
N/A |
| Onconase |
Alfacell
Corporation (ACEL) |
RNA |
Suspended (Clinical
Detail) |
N/A |
0%
(Same As Avg.) |
N/A |
| OSI-461 |
OSI
Pharmaceuticals, Inc. (OSIP) |
Phosphodiesterase |
Suspended (Clinical
Detail) |
N/A |
0%
(Same As Avg.) |
N/A |
| TG4010
|
Transgene
S.A. (TRGNY) |
MUC-1 |
Suspended (Clinical
Detail) |
N/A |
0%
(Same As Avg.) |
N/A | | |
| |
 |
Renal cell
carcinoma (RCC) is the most common type of kidney
cancer. It accounts for more than 90% of malignant
kidney tumors. Renal cell cancer (also called
kidney cancer or renal adenocarcinoma) is a
disease in which malignant (cancer) cells are
found in the lining of tubules (very small tubes)
in the kidney. The tiny tubules in the kidneys
filter and clean the blood, taking out waste
products and making urine.
Renal cell carcinoma accounts for approximately
3% of adult malignancies. The age-adjusted
incidence of renal cell carcinoma has been rising
by 3% per year. Approximately 31,200 new cases of
RCC were diagnosed in the year 2000, and more than
11,900 affected individuals died. RCC is
characterized by a lack of early warning signs,
diverse clinical manifestations, resistance to
radiation and chemotherapy, and infrequent but
reproducible responses to immunotherapy agents
such as interferon alpha and interleukin (IL)-2.
There are 5 main types of renal cell carcinoma
that are identified by examining the tumor under a
microscope: clear cell, papillary, chromophobe,
collecting duct, and "unclassified."
| | |
| | | |
